Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando, Florida.

Articles

Understanding the Nature of a KRAS G12C Mutation in NSCLC

December 9th 2022

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

October 17th 2022

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer

October 17th 2022

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations

October 10th 2022

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Further Molecular Testing in Early-Stage Metastatic Breast Cancer

October 10th 2022

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer

September 26th 2022

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

Clinical Scenario: A 74-Year-Old Man with Lung Cancer

September 26th 2022

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

Discussing Biomarker Testing with Patients

September 20th 2022

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Use of Liquid Biopsies in Breast Cancer

September 20th 2022

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Challenges of Biomarker Testing in Breast Cancer

September 12th 2022

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Biomarker Testing Interpretation in Breast and Lung Cancer

September 12th 2022

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Choosing a Molecular Testing Panel for Solid Tumors

September 6th 2022

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Currently Targetable Mutations in Lung and Breast Cancer

September 6th 2022

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer

September 3rd 2022

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

PD-L1 Expression and IO Therapy in Lung and Breast Cancer

September 3rd 2022

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Using Molecular Testing to Guide Treatment Decisions

August 29th 2022

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

Available Molecular Tests for Solid Tumors

August 29th 2022

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Unmet Needs and Future Directions in the Management of CIM

July 22nd 2022

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

An Overview of Trilaciclib Safety and Patient QOL Outcomes

July 22nd 2022

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC

July 15th 2022

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.